ArticleCureus2025
Identification of the Potential Pharmacotherapeutic Risk in Hospitalized Geriatric Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Drug Burden Index and its association with postural balance and falls among community-dwelling older adults.Frontiers in medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGeriatric patients need carefully tailored pharmacotherapeutic approaches to minimize the risks of inappropriate treatment and hospitalizations. In Slovakia, there is a lack of studies documenting the medication use patterns in hospitalized geriatric patients. The primary outcome of our study was to identify potential pharmacotherapeutic risks in hospitalized geriatric patients.
methodsWe performed a retrospective analysis of the medical records from 122 patients (65 years and older) hospitalized in the geriatric department. Potential pharmacotherapeutic risk was assessed by identifying potential drug-drug interactions (PDIs) and potentially inappropriate medications (PIMs). PDIs were identified using the Lexicomp® database, and PIMs were evaluated using the EU(7)-PIM list. PDIs were classified into five severity categories: A (unknown), B (minor), C (moderate), D (major), and X (contraindicated). Patients' medication was labeled as "PDIs in the therapy" or "PIMs in the therapy" based on the presence of PDIs or PIMs. If PDIs were identified, the patient was labeled "PDI in therapy"; if PIMs were found, the label "PIMs in the therapy" was applied.
resultsPolypharmacy (61.5%, 75 patients) and hyperpolypharmacy (16.4%, 20 patients) were highly prevalent. PDIs were identified in 80.3% of patients (98 patients). Out of the total 417 PDIs, eight were contraindicated (type X) and 47 were classified as major (type D) interactions. PIMs were used by 73.8% of patients (90 patients), with the most common being pantoprazole (37.7%, 46 patients), alprazolam (27.8%, 34 patients), and digoxin (15.6%, 19 patients). We found a moderate relationship between the number of used drugs and the number of PIMs (ρ = 0.574, R
conclusionOur results underscore the urgent need for medication reviews by hospital pharmacists and the active promotion of drug deprescription among clinicians.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.